ALKS Alkermes plc. stock chart & analysis
Conviction 35HealthcareScan · Fri, Nov 6, 2026Alkermes plc. (ALKS) closed at $45.90 (+3.05%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 60, RS Rating 89, -17.5% from its 52-week high, +64.1% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
ALKS technical analysis
Trend
ALKS is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 5.1% above the 50-day ($43.71) and 12.6% above the 200-day ($40.80). ADX(14) at 21 points to a moderate trend. It meets 6 of 8 trend-template criteria.
Momentum
RSI(14) is 60, in the bullish half of its range. The MACD histogram is positive. A bullish RSI divergence is in place. A bullish MACD divergence is in place. Its RS Rating of 89 puts its weighted 12-month performance ahead of about 89% of the US market.
Volume and volatility
Volume on the latest session ran 1.1× its 20-day average. It trades about $80.0M a day on average. ATR(14) is $1.66, 3.6% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.08) shows distribution.
Key levels
The chart pattern's support is $39.04 and its resistance $47.41. The 52-week range is $27.00 to $55.67; price is 17.5% below the high and 70.1% above the low. The VWAP anchored at the 52-week high is $46.10, above price.
Performance
ALKS returned +1.3% (1 week), +14.5% (1 month), -7.0% (3 months), +31.2% (6 months), +47.8% (1 year), +64.1% (year to date).
About Alkermes plc.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Pharmaceutical Preparations · Listed 1991 · 2,050 employees
Congress activity
Disclosed STOCK Act trades in ALKS · 2 recent
Insider activity
SEC Form 4 transactions in ALKS · open-market 3 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Gaffin David Joseph EVP, CLO, Alkermes, Inc. · Ordinary Shares · 2026-11-03 | Sell | 2.04K | $94K | 2026-11-03 | 2026-11-03 |
Reed Joshua SVP, Chief Financial Officer · Ordinary Shares · 2026-10-08 | Exercise | 9.16K | — | 2026-10-08 | 2026-10-09 |
Reed Joshua SVP, Chief Financial Officer · Ordinary Shares · 2026-10-08 | Tax | 4.07K | $163K | 2026-10-08 | 2026-10-09 |
Reed Joshua SVP, Chief Financial Officer · Restricted Stock Unit Award · 2026-10-08 | Exercise | 9.16K | — | 2026-10-08 | 2026-10-09 |
Whitaker Anne Clem Director · Restricted Stock Unit Award · 2026-10-07 | Grant | 7.24K | — | 2026-10-07 | 2026-10-09 |
Whitaker Anne Clem Director · Non Qualified Stock Option (Right to Buy) · 2026-10-07 | Grant | 18K | — | 2026-10-07 | 2026-10-09 |
Gaffin David Joseph EVP, CLO, Alkermes, Inc. · Ordinary Shares · 2026-10-02 | Sell | 2.03K | $83K | 2026-10-02 | 2026-10-02 |
Hopkinson Craig C. EVP R&D, Chief Medical Officer · Ordinary Shares · 2026-09-01 | Exercise | 5K | $123K | 2026-09-01 | 2026-09-01 |
Hopkinson Craig C. EVP R&D, Chief Medical Officer · Ordinary Shares · 2026-09-01 | Sell | 9K | $423K | 2026-09-01 | 2026-09-01 |
Hopkinson Craig C. EVP R&D, Chief Medical Officer · Employee Stock Option (Right to Buy) · 2026-09-01 | Exercise | 5K | — | 2026-09-01 | 2026-09-01 |
SEC filings
EDGAR filings in ALKS · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.